Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Next Previous
Trial Profile

A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tuspetinib (Primary) ; Azacitidine; Venetoclax
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms APTIVATE; TUSCANY; TUSCANY Triplet Trial
  • Sponsors Aptose Biosciences; Hanmi Pharmaceutical

Most Recent Events

  • 03 Nov 2025 Results presented in the Aptose Biosciences Media Release.
  • 03 Nov 2025 According to an Aptose Biosciences media release,data from this trial will be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting is scheduled to take place December 6-9, 2025, in Orlando, Florida.
  • 16 Oct 2025 According to an Aptose Biosciences media release, data from this study are being presented as a poster presentation at the European School of Haematology (ESH) 7th International Conference on Acute Myeloid Leukemia.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top